Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia.
Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia.
复制标题
DOI：
10.1016/s0953-6205(03)90001-x
复制
发表时间：
2003-10-01
影响因子：
8
通讯作者：
Ilkova, Hasan
中科院分区：
文献类型：
--
作者：
Damci, Taner;Tatliagac, Serkan;Ilkova, Hasan
背景：2型糖尿病患者常发生Hercidemia。贝特类药物是一组有效降低甘油三酯，增加HDL，改善糖尿病和非糖尿病患者预后的药物。然而，贝特类药物对血糖控制、血压、空腹血清胰岛素和瘦素浓度的影响尚不清楚。本研究探讨了非诺贝特治疗高脂血症2型糖尿病患者是否会导致代谢控制、体重指数、瘦素、游离脂肪酸、血浆胰岛素和血压的变化。方法：31例血清甘油三酯水平在250 - 400 mg/dl之间的2型糖尿病患者纳入研究。他们被给予250毫克/天的非诺贝特，每天一次，为期3个月。整个研究期间，降糖和降压治疗保持不变。结果如下：非诺贝特治疗导致更好的血糖控制，如通过更低的空腹和餐后血糖和HbAlc、降低的空腹血清胰岛素和瘦素水平、以及高甘油三酯血症和血清游离脂肪酸的减少、以及HDL胆固醇的增加所证明的。血压、体重指数和LDL保持不变。非诺贝特在所有患者中耐受良好。结论：非诺贝特治疗高脂血症2型糖尿病患者不仅在血脂方面有益，而且在血糖控制和胰岛素抵抗方面也有益。
Background: Hertriglyceridemia is commonly encountered in type 2 diabetic patients. Fibrates are a group of drugs that efficiently decrease triglycerides, increase HDL, and improve the prognosis in both diabetic and nondiabetic patients. However, the effects of fibrates on glycemic control, blood pressure, fasting serum insulin, and leptin concentrations are not clear. The present study addresses the question of whether fenofibrate treatment in hypertriglyceridemic type 2 diabetic patients leads to changes in metabolic control, body mass index, leptin, free fatty acids, plasma insulin, and blood pressure. Methods: Thirty-one type 2 diabetic patients who had serum triglyceride levels between 250 and 400 mg/dl were included in the study. They were given 250 mg/day fenofibrate once daily for 3 months. Antidiabetic and antihypertensive treatments were kept unchanged throughout the study. Results: Fenofibrate treatment resulted in better glycemic control, as evidenced by lower fasting and postprandial blood glucose and HbAlc, decreased fasting serum insulin and leptin levels, as well as a reduction in hypertrigyceridemia and serum free fatty acids, and an increase in HDL cholesterol. Blood pressure, body mass index, and LDL remained unchanged. Fenofibrate was well tolerated in all patients. Conclusion: Fenofibrate treatment in hypertriglyceridemic type 2 diabetic patients is beneficial not only in terms of lipid profile, but also for glycemic control and insulin resistance.